Comparison
Trevogrumab vs ACE-031
Selective myostatin-neutralization vs broad-spectrum ligand trapping for lean mass retention and gain.
Trevogrumab
Anti-Myostatin Monoclonal Antibody
ACE-031
Myostatin / ActRIIB Ligand Trap (Fc-Fusion Biologic)
Effectiveness Profile
At a Glance
| Trevogrumab | ACE-031 | |
|---|---|---|
| Type | Other | Other |
| Legal status | Research | Research |
| Half-life | ~2–4 weeks (IgG4 class estimate) | 10–15 days |
| Preferred route | IV | SubQ |
| Dose frequency | custom | weekly |
| Beginner dose | 200–200 mg | 0.5–1 mg |
| Intermediate dose | 400–400 mg | 1–2 mg |
| Advanced dose | 400–400 mg | 2–3 mg |
| Cycle length | 26–52 wks | 4–8 wks |
| Bioavailability | 100% | 70% |
| Time to peak | 2h | 168h |
| Active duration | 672h | 720h |
| Storage | 2–8°C refrigerated; do not freeze; protect from light | Lyophilized: 2–8°C refrigerated. Reconstituted: 2–8°C, use within ~28 days. |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Trevogrumab wins for precise myostatin blockade, safety in the GLP-1/weight-loss context, and clean muscle-sparing synergy with GLP-1s. Minimal off-target activity means reduced risk of activin/GDF11-related vascular effects.
ACE-031 wins for raw lean mass gain and rapid onset after a single SC injection. Its decoy-receptor mechanism hits multiple muscle-catabolism pathways and delivers visible mass accrual, though with higher risk of vascular side effects due to cross-reactivity.
Pick A or B?
Pick Trevogrumab if:
- The research model is focused on protecting lean mass during aggressive weight loss (especially alongside GLP-1 agonists).
- Activin A/GDF11 sparing is a priority—avoiding additional vascular or hematological risk signals.
- Clean pharmacology with minimal unexpected side effects is required.
- The project is long-term and demands safety data from large studies.
- The goal is muscle preservation over new muscle accretion.
Pick ACE-031 if:
- The model is exploring direct increases in muscle mass (lean mass accretion) over a short research window.
- Sourcing is via research-chem vendors with established chains—IgG4 mAbs are not accessible, while fusion-proteins sometimes are.
- There is willingness to actively monitor and manage vascular side effects (telangiectasia, epistaxis).
- The aim is to stack multiple myostatin/activin pathway inhibitors for synergistic muscle growth.
- A rapid, prominent effect is prioritized over ultra-clean selectivity.
Where to Buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Trevogrumab· Buy Trevogrumab 1mg (1 vial) - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Trevogrumab
- ACE-031· Buy ACE-031 1 mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy ACE-031